Metabolomics in renal cell carcinoma : From biomarker identification to pathomechanism insights
Copyright © 2020 Elsevier Inc. All rights reserved..
Renal cell carcinoma (RCC) is a frequently diagnosed cancer with high prevalence, which is inversely associated with survival benefit. Although myriad studies have shed light on disease causality, unfortunately, thus far, RCC diagnosis is faced with numerous obstacles partly due to the insufficient knowledge of effective biomarkers, hinting deeper mechanistic understanding are urgently needed. Metabolites are recognized as final proxies for gene-environment interactions and physiological homeostasis as they reflect dynamic processes that are ongoing or have been taken place, and metabolomics may therefore offer a far more productive and cost-effective route to disease discovery, particularly within the arena for new biomarker identification. In this review, we primarily expatiate recent advances in metabolomics that may be amenable to novel biomarkers or therapeutic targets for RCC, which may expand our armaments to win more bettles against RCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:695 |
|---|---|
| Enthalten in: |
Archives of biochemistry and biophysics - 695(2020) vom: 30. Nov., Seite 108623 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Yuan-Yuan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 07.12.2020 Date Revised 14.12.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.abb.2020.108623 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316092851 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316092851 | ||
| 003 | DE-627 | ||
| 005 | 20231225160332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.abb.2020.108623 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1053.xml |
| 035 | |a (DE-627)NLM316092851 | ||
| 035 | |a (NLM)33039388 | ||
| 035 | |a (PII)S0003-9861(20)30632-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Yuan-Yuan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolomics in renal cell carcinoma |b From biomarker identification to pathomechanism insights |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.12.2020 | ||
| 500 | |a Date Revised 14.12.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a Renal cell carcinoma (RCC) is a frequently diagnosed cancer with high prevalence, which is inversely associated with survival benefit. Although myriad studies have shed light on disease causality, unfortunately, thus far, RCC diagnosis is faced with numerous obstacles partly due to the insufficient knowledge of effective biomarkers, hinting deeper mechanistic understanding are urgently needed. Metabolites are recognized as final proxies for gene-environment interactions and physiological homeostasis as they reflect dynamic processes that are ongoing or have been taken place, and metabolomics may therefore offer a far more productive and cost-effective route to disease discovery, particularly within the arena for new biomarker identification. In this review, we primarily expatiate recent advances in metabolomics that may be amenable to novel biomarkers or therapeutic targets for RCC, which may expand our armaments to win more bettles against RCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Cancer | |
| 650 | 4 | |a Metabolite | |
| 650 | 4 | |a Metabolomic | |
| 650 | 4 | |a Renal cell carcinoma | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 700 | 1 | |a Hu, He-He |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yan-Ni |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jing-Ru |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hai-Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Jian-Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Ying-Yong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of biochemistry and biophysics |d 1951 |g 695(2020) vom: 30. Nov., Seite 108623 |w (DE-627)NLM000012998 |x 1096-0384 |7 nnns |
| 773 | 1 | 8 | |g volume:695 |g year:2020 |g day:30 |g month:11 |g pages:108623 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.abb.2020.108623 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 695 |j 2020 |b 30 |c 11 |h 108623 | ||